IL-7 therapy: Oncology and beyond
Time: 11:30 am
day: Day One
Details:
- NT-I7 (efineptakin alfa, a long-acting human IL-7) clinical development
- NT-I7 in combination with checkpoint inhibitors
- Potential clinical biomarkers in IL-7 treatment